Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Horizon, Domainex Working on Cancer Research

By Drug Discovery Trends Editor | August 6, 2012

Horizon Discovery Ltd., a leading provider of research tools to support the development of personalized medicines, announced it has signed an agreement with Domainex to support Domainex’s TBK1/ IKKe oncology research and development program, which is conducted in collaboration with The Institute of Cancer Research, London. Under the terms of the agreement, Horizon will profile a number of lead compounds against a panel of X-MAN isogenic disease model human cell lines, which accurately model the mutations found in cancer cells.

Profiling of Domainex’s lead TBK1/IKKe dual inhibitor molecules against the X-MAN cell lines will enable identification of the effect of individual mutations on drug activity and resistance and prediction of which patient sub-groups will respond.  This will help guide the medicinal chemistry optimization program and will provide important patient stratification data for future partnering.

“Horizon’s oncology and genome editing expertise are a valuable complement to our in-house biochemistry, medicinal chemistry and computer aided drug design capabilities,” commented Eddy Littler, CEO of Domainex. “We look forward to working together to efficiently and cost-effectively develop a drug molecule for this important target. We also look forward to future collaborations with Horizon on Domainex’s epigenetic pipeline in oncology and with the wide number of projects that Domainex supports on behalf of its clients”

Kam Dhaliwal, Director of Business Development, Horizon said: “We are delighted that Domainex has chosen to collaborate with Horizon on their lead program, and look forward to leveraging our   Discovery Toolbox and Oncology expertise to help guide the program.”

Horizon’s Discovery Toolbox is based on its proprietary precision rAAV-mediated genome editing technology (GENESIS), over 450 X-MAN human isogenic cell lines that more accurately model patient genetics (known as patients in a test tube), and 2D and 3D phenotypic assays. The Toolbox enables the recapitulation of the patient situation in vitro and allows screening of the most important activated cancer genes and pathways found in patients, under conditions that mimic the micro environment of the disease.

Date: August 6, 2012
Source: Horizon Discovery Ltd.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50